Product Images Lenalidomide

This appears to be a chart or graph related to the survival probability and progression free survival (PFS) of subjects under various treatments. The treatments referenced include Rd Continuous, Rel18, and MPT. The chart displays survival probabilities and event numbers over time in months. However, insufficient information is available to provide a definite conclusion.*

This appears to be a table of clinical trial results with data on survival rates and number of subjects at risk, with comparison between different treatments including "Rd Continuous", "Rd18", and "MPT". The specific conditions, purpose, and context of the trial are not available in this text.*

This seems to be a clinical trial report evaluating the effectiveness of a medication called Lenalidomide compared to a placebo. The results suggest that patients who took Lenalidomide had a significantly longer Progression-free Survival (PFS), compared to those who took placebo. The study reports some numerical data and a graphic representation of the outcomes. The text included various terms related to statistical measures, patient groups, and medical concepts.*

This appears to be a clinical trial report for the comparison of the drug Lenalidomide and a placebo in terms of progression-free survival. The report includes data such as hazard ratios, median survival times, and the number of subjects at risk for each group. It seems that Lenalidomide has a longer progression-free survival compared to the placebo.*

This is a summary of the results of a study, where the proportion of subjects achieving different levels of response to a treatment was evaluated. The treatment consisted of Lenalidomide/Dex, and the results showed a significant improvement in the time to progression (30 months) with an HR of 0.285 and a Log Rank p < 0.001.*

The text indicates the results of a study that compares the use of Lenalidomide/Dex versus PlacsboiDex to treat a medical condition. The numbers presented in the "Proportion of Subjects" section suggest a breakdown of the study group, but the context is not clear. The HR (Hazard Ratio) is 0.324 with a 95% CI (Confidence Interval) of 0.240-0.438, and the Log Rank p-value is less than 0.0001. The study evaluated the time to progression in months and presented the results in a graph.*

This is a medication called Lenalidomide Capsules that requires prescription (Rx only). It contains a warning of potential birth defects in humans, so it must be dispensed by pharmacists and taken with caution. The bottle has 28 capsules, each with 25 mg of Lenalidomide. The usual dose and manufacturing information are provided. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C to 0°C (SQ" F to 86°F). The manufacturer is Cipla Ltd, located in Winnipeg, Manitoba, Canada, and manufactured for Cipla USA, Inc., located in Warren, NJ.*